Despite the termination of clinical trials for GSK3α/β inhibitors in Alzheimer's disease (AD) treatment, there is a pressing need for novel therapeutic strategies targeting GSK3α/β. The gene discussed is GSK3A; the disease is early-onset autosomal dominant Alzheimer disease.